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OBJECTIVES The purpose of this study was to investigate the regulation of beta-adrenergic agonist-induced
apoptosis by endothelin-1 (ET-1) in cardiac myocytes.
BACKGROUND Numerous hormonal factors including norepinephrine and ET-1 are activated in patients
with heart failure. These factors may be involved in the positive and negative regulation of
myocardial cell apoptosis observed in failing hearts. Recently, it has been shown that
norepinephrine can induce myocardial cell apoptosis via a beta-adrenergic receptor-
dependent pathway.
METHODS Primary cardiac myocytes were prepared from neonatal rats. These cells were stimulated with
the beta-adrenergic agonist isoproterenol (ISO) in the presence or absence of ET-1.
RESULTS The administration of 1027 mol/liter of ET-1 completely blocked Iso-induced apoptosis. An
endothelin type A receptor antagonist, FR139317, negated the inhibitory effect of ET-1 on
apoptosis, while the endothelin type B receptor antagonist BQ788 did not show such a
negation. Endothelin-1 also inhibited apoptosis induced by a membrane-permeable cAMP
analogue (8-Br-cAMP), which bypassed Gi. The effect of ET-1 was neutralized by an
MEK-1-specific inhibitor (PD098059), a phosphatidylinositol 39-kinase inhibitor (wortman-
nin) and its downstream pp70 S6-kinase inhibitor, rapamycin.
CONCLUSIONS These findings suggest that ET-1 represents a protective factor against myocardial cell
apoptosis in heart failure and that this effect is mediated mainly through endothelin type A
receptor-dependent pathways involving multiple downstream signalings in cardiac myocytes.
(J Am Coll Cardiol 2000;36:1411–8) © 2000 by the American College of Cardiology
Apoptosis, or programmed cell death, is an active, gene-
directed process in which cells initiate their own death in
response to internal or external stimuli. This mode of death
serves as an orderly means for multicellular organisms to
eliminate unwanted cells without adversely affecting sur-
rounding tissue. Thus, apoptosis is a key mechanism of
normal tissue development in the fetus and of cell replace-
ment in certain adult tissues (e.g., the thymus), and is most
often encountered in cells that are progressing through the
cell cycle (1–4). However, accumulating evidence suggests
that terminally differentiated adult cardiac myocytes un-
dergo apoptosis in various animal models of heart failure.
These include models of rapid ventricular pacing (5,6) and
pressure overload due to aortic constriction (7), and aged
spontaneously hypertensive rats (8). Because adult muscle
cells have lost their proliferative capacity, the loss of viable
cardiac myocytes due to apoptosis results in a further
decrease in global cardiac function. As such, identification
of the signaling pathways that mediate cardiac myocyte cell
death and survival is crucial to the ultimate elucidation of
the molecular basis of cardiac muscle failure.
Despite an increasing body of evidence concerning myo-
cardial cell apoptosis in vivo, little is known regarding the
relevant physiologic stimuli. The control of programmed
cell death is dependent on a balance between inhibitors and
inducers of apoptosis. Because a number of systemic and
local humoral factors are activated in congestive heart failure
(9,10), they may possibly play positive and negative roles in
the regulation of myocardial cell apoptosis. Norepinephrine
is one such factor; the elevation of norepinephrine in plasma
closely correlates with the severity and poor prognosis of
heart failure (10). It has recently been shown that norepi-
nephrine can induce apoptosis in cultured neonatal cardiac
myocytes via a beta-adrenergic pathway (11,12), suggesting
that it might be one of the factors involved in myocardial
cell apoptosis in heart failure in vivo.
Another factor activated in congestive heart failure is
endothelin-1 (ET-1), a 21-residue peptide originally iso-
lated from vascular endothelium (13). The levels of ET-1 in
plasma and in ventricular myocardium are markedly in-
creased in human and animal models of heart failure
(14–16). Endothelin-1 exerts diverse physiological actions
including vasoconstriction and growth-promotion. More-
over, ET-1 is sufficient to induce the myocardial cell
hypertrophy associated with the reactivation of the fetal
gene program (17,18). These various effects are mediated by
two distinct subtypes of G protein-coupled heptahelical
receptors, ETA and ETB, expressed in a wide variety of
tissues (19,20). It was recently reported that ET-1 is a
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survival factor in actively proliferating cells such as smooth
muscle cells (21) and fibroblasts (22). However, it is unclear
whether this survival effect of ET-1 also occurs in postmi-
totic cells such as cardiac myocytes, and if so, whether the
regulation of apoptosis by ET-1 in the postmitotic cell type
is mediated through intracellular signaling pathways similar
to those used in mitotic cells. Thus, the present study was
conducted to determine the effect of ET-1 on the beta-
adrenergic stimulation-induced apoptosis of cardiac myo-
cytes.
EXPERIMENTAL PROCEDURES
Cell culture. Primary ventricular cardiac myocytes were
prepared as previously described (12,23). Briefly, hearts
from one- to two-day-old Sprague-Dawley rats were re-
moved, the ventricles were pooled, and the ventricular cells
were dispersed by digestion with pancreatin (Life Technol-
ogies, Gaithersburg, Maryland). The cells were preplated
for 1 h to enrich the culture with myocytes (90% to 95% of
cells after this step). Cells were plated at a high density
(1,000 cells/mm2) on 60-mm tissue culture dishes (Prima-
ria, Falcon; Becton Dickinson, Lincoln Park, New Jersey)
and cultured in media consisting of Hanks’ salts plus
minimal essential medium (MEM) vitamin stock, MEM
amino acids, MEM nonessential amino acids, 2 mmol/liter
L-glutamine, 0.67 mmol/liter glycine, 0.92 mmol/liter hy-
poxanthine, 19.6 mmol/liter NaHCO3 (pH 7.1 to 7.2),
penicillin, streptomycin, and 10% (vol/vol) fetal bovine
serum (all from Gibco BRL, Gaithersburg, Maryland) at
37°C, 5% CO2.
Reagents. Synthetic ET-1 and ETB receptor agonist (IRL
1620) were purchased from Peptide Institute (Osaka, Ja-
pan). The ETB receptor antagonist BQ788 was from
Calibiochem-Novabiochem (La Jolla, California). The
8-Br-cAMP, wortmannin, and rapamycin were from Sigma
Aldrich (Tokyo, Japan). The ETA receptor antagonist
FR139317 was provided by Fujisawa Research Laboratory
(Osaka, Japan).
Nucleosomal ladder assay. Forty-eight hours after plating,
the neonatal rat cardiac myocytes were washed twice with
serum-free medium and cultured in serum-free medium in
the presence or absence of ET-1 and isoproterenol (Iso) or
8-Br-cAMP for 48 h. The cells were then harvested by
scraping into the medium. After centrifugation at 500g for
5 min at 4°C, the cells were lysed in lysis buffer and
subjected to a nucleosomal ladder assay using a commercial
kit (Takara Biomedicals, Shiga, Japan) according to the
manufacturer’s recommendations. The presence of charac-
teristic 180–200-bp multiple oligonucleosomal fragmenta-
tion was examined on 1.5% agarose gels stained with
SYBR™Green I (Takara Biomedicals, Shiga, Japan).
In situ labeling of apoptotic cells and their quantitative
analysis. Terminal deoxynucleotidyl transfer-mediated end
labeling of fragmented nuclei (TUNEL assay) was per-
formed on cardiomyocytes that had been plated on flask-
style glass slides (Nalgen Nunc, Naperville, Illinois). The in
situ TUNEL assay was then performed in accordance with
the manufacturer’s protocol for cultured cells (Takara Bio-
medicals) after fixing the cells in 10% neutral buffered
formalin for 10 min at room temperature. Individual nuclei
were visualized at 3400 for quantitative analysis. An aver-
age of 400 to 500 nuclei from random fields were analyzed
in each slide. The apoptotic index (percentage of apoptotic
nuclei) was calculated as (apoptotic nuclei/total nuclei)
3100%. Sample indicators were concealed during scoring,
and samples from at least three independent experiments
were scored per group.
Statistical analysis. Data are presented as mean 6 SE.
Statistical comparisons were performed using the unpaired
two-tailed Student t test or analysis of variance with Scheffe
test when appropriate, with a probability value less than 0.05
taken to indicate significance.
RESULTS
Endothelin-1 inhibits beta-adrenergic agonist-induced
apoptosis in cardiac myocytes. Neonatal cardiac myocytes
retain some ability to undergo mitosis. We investigated
whether these cells divide in response to stimulation with
ET-1 under our experimental condition. Neonatal cardiac
myocytes were treated with saline or ET-1 (1027 mol/liter)
in a serum-free medium for 48 h. These cells were pulsed
with 5-bromo-29-deoxy-uridine (BrdU) between 46 and
48 h after stimulation; then BrdU uptake in these cells was
estimated by enzyme-linked immunosorbant assay (Amer-
sham Pharmacia Biotech, Buckinghamshire, UK). The
BrdU uptake was very low (almost undetectable) and was
not increased by ET-1 stimulation in neonatal cardiac
myocytes.
In contrast, in COS7 cells, which can actively proliferate,
stimulation with the same concentration of ET-1 increased
the uptake of BrdU by 6.7-fold. These results indicate that
ET-1 stimulation does not increase DNA synthesis in
neonatal cardiac myocytes under our experimental condi-
tion.
To determine the effects of ET-1 on beta-adrenergic
agonist-induced myocardial cell apoptosis, neonatal rat
cardiac myocytes were treated with saline, a beta-adrenergic
agonist (1025 mol/liter of Iso) alone or Iso plus ET-1
(1027 mol/liter) in the serum-free condition for 48 h. In our
experimental conditions in which cells were plated at a high
density, serum deprivation alone did not increase the num-
ber of TUNEL-positive cells (,10%) (Fig. 1A). As shown
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increased the number of TUNEL-positive cells (.40%).
These positive cells may specifically indicate the presence of
internucleosomal DNA fragmentation, as no positive cells
were found when we omitted the terminal deoxytransferase
treatment (Fig. 1C). The cells stimulated with Iso displayed
small condensed nuclei, cell shrinkage, and nuclear frag-
mentation, consistent with the morphologic features of
apoptosis (Fig. 1C). Fewer myocardial cells treated with
ET-1 in addition to Iso were positive for internucleosomal
cleavage by TUNEL staining (Fig. 1D) compared with the
cells treated with Iso alone (Fig. 1B).
As shown in Figure 2, lane 4, 1027 mol/liter of ET-1 was
sufficient to produce a complete blockade of Iso-stimulated
increase in TUNEL-positive cells. Figure 3 (lane 2) shows
the Iso-induced typical ladder formation of fragmented
internucleosomal DNA in agarose gels, a hallmark of
apoptosis. As shown in lane 3 of Figure 3, ET-1 completely
inhibited the internucleosomal cleavage of genomic DNA in
Iso-stimulated cardiac myocytes. These findings are evi-
dence that ET-1 has an antiapoptotic effect on beta-
adrenergic agonist-induced apoptosis in cardiac myocytes.
The ETA receptor-dependent pathway mediates the an-
tiapoptotic effect of ET-1. To characterize the ET-1
receptor subtype mediating the inhibition of apoptosis in
cardiac myocytes, we examined whether subtype-specific
receptor antagonists can abrogate the protective effect of
ET-1. Both FR139317 (24,25) and BQ788 (26) are potent,
Figure 1. ET-1-mediated inhibition of Iso-induced apoptosis in cultured neonatal rat cardiac myocytes. TUNEL-stained myocytes. (A) In the absence of
Iso or ET-1; (B and C) in the presence of Iso (1025 mol/liter); (D) in the presence of Iso plus ET-1 (1027 mol/liter). Terminal deoxytransferase was omitted
in C. Arrows show cells with evidence of apoptosis, including chromatin condensation.
Figure 2. Complete inhibition by ET-1 of Iso-induced apoptosis. Cul-
tured cardiac myocytes were treated for 48 h in serum-free media in the
presence or absence of Iso (1025 mol/liter) and the indicated concentra-
tions of ET-1. TUNEL-positive nuclei were counted and are expressed as
the percentage of total nuclei. An average of 400 to 500 nuclei were
counted from random fields in each slide. Results are the mean 6 SE of
three independent experiments.
Figure 3. ET-1-mediated inhibition of genomic DNA fragmentation in
cardiac myocytes. Genomic DNA was isolated from myocytes maintained
for 48 h in serum-free media in the presence or absence of Iso (1025
mol/liter) and ET-1 (1027 mol/liter) as indicated and loaded on a 1.5%
agarose gel. M, molecular marker.
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specific antagonists of ETA and ETB receptors, respectively.
It has been shown that 1027 mol/liter of FR139317 almost
completely (.99%) inhibits the binding of 125I-ET-1 to the
ETA receptor but does not inhibit (,2%) the binding to the
ETB receptor (25). As shown in Figure 4, lane 6,
1027 mol/liter of FR139317 increased the number of
TUNEL-positive myocytes to an extent similar to that
observed with Iso stimulation alone. However, the same
concentration of FR139317 alone did not increase the
number of TUNEL-positive cells (Fig. 4, lane 2), suggest-
ing that this agent specifically blocked the protective effect
of ET-1.
In contrast, 1026 mol/liter of the ETB antagonist BQ788
(26) only partially negated the inhibitory effect of ET-1 on
apoptosis (Fig. 4, lane 7). In addition, the ETB receptor
agonist IRL1620 (27,28) did not mimic the inhibitory effect
of ET-1 (Fig. 4, lane 8). These results indicate that the
apoptotic inhibitory effect of ET-1 is mediated mainly by
the ETA receptor.
The ETA receptor is coupled with both Gq and Gi. The
ETA receptor-mediated Gi-signaling can inhibit adenylate
cyclase activity (29). To investigate whether Gi pathways are
required for the inhibition of Iso-induced apotosis by ET-1,
we utilized a cell-permeable cAMP analogue, 8-Br-cAMP
(3 3 1022 mol/liter), which can increase intracellular
cAMP levels independent of Gi-coupled adenylate cyclase.
Administration of 8-Br-cAMP also increased the number
of TUNEL-positive cardiac myocytes to an extent similar to
that produced by Iso (Fig. 5, lane 2). Notably, ET-1 almost
completely inhibited the 8-Br-cAMP-stimulated increase
of apoptosis as well (Fig. 5, lane 3). These findings suggest
the Gi-dependent pathways are not indispensable to the
apoptotic inhibitory effect by ET-1.
PD098059, wortmannin and rapamycin neutralized the
protective effect of ET-1. We searched for intracellular
signals essential for the ET-1-induced cell survival by a
pharmacological approach. To determine whether the MAP
kinase cascade is required for the ET-1 inhibition of
apoptosis in cardiac myocytes, we utilized PD098059, a
specific MEK inhibitor that selectively inhibits MEK-1
activity (30,31). A previous study confirmed that
1025 mol/liter of PD098059 specifically inhibited the
ERK1 and ERK2 activity in cardiac myocytes (32). As
shown in Figure 6 (lane 7), 1025 mol/liter of PD098059
negated the inhibitory effects of ET-1 on myocardial cell
Figure 4. Effects of receptor subtype antagonist or agonist on ET-1-mediated inhibition of apoptosis. Cardiac myocytes were cultured in serum-free media
in the presence or absence of Iso (1025 mol/liter), ET-1 (1027 mol/liter), an ETA receptor antagonist (FR139317), an ETB receptor antagonist (BQ788)
or an ETB receptor agonist (IRL1620) as indicated for 48 h. The % TUNEL-positive nuclei values were calculated by counting an average of 400 to
500 nuclei in each slide. Values are mean 6 SE of four independent experiments.
Figure 5. Complete inhibition by ET-1 of 8-Br-cAMP-induced apopto-
sis. Cardiac myocytes were cultured in serum-free media in the presence or
absence of 8-Br-cAMP (3 3 1022 mol/liter) and ET-1 (1027 mol/liter) as
indicated for 48 h. The % TUNEL-positive nuclei values were calculated
by counting an average of 400 to 500 nuclei in each slide. Values are
mean 6 SE of two independent experiments.
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apoptosis. To exclude the possibility of a nonspecific cyto-
toxic effect of PD098059, we tested whether it was capable
of inducing cell death in the serum-free condition. We
found that 1025 mol/liter of PD098059 alone did not
induce apoptosis compared with saline stimulation (Fig. 6,
lane 2). This result suggested that PD098059 might block
the downstream signaling pathway by which ET-1 prevents
apoptosis.
To determine whether the effect of ET-1 on the inhibi-
tion of apoptosis involved the phosphatidylinositol 39-
kinase (PI3) pathway, we used the specific PI39-kinase
inhibitor wortmannin. Wortmannin has previously been
shown to inhibit PI39-kinase activity completely at the
concentration of 1027 mol/liter (33,34). Cardiac myocytes
were incubated with Iso (1025 mol/liter), ET-1
(1027 mol/liter) and wortmannin (1027 mol/liter). This
concentration of wortmannin blocked the inhibition of
apoptosis by ET-1 as demonstrated by increased TUNEL-
positive cells (Fig. 6, lane 8). The 70-kD S6 kinase pp70S6K
is known to play a role in the signaling cascade initiated by
PI39-kinase (35–37). The inhibitor rapamycin is known to
block the activation of pp70S6K downstream of PI39-kinase
(38–45). A previous study demonstrated that 1028 mol/
liter of rapamycin was sufficient to inhibit the pp70S6K
activity in cardiac myocytes completely (46). This concen-
tration of rapamycin negated the inhibitory effects of ET-1
on myocardial cell apoptosis (Fig. 6, lane 9), while this
concentration of rapamycin alone did not induce apoptosis
compared with saline stimulation (Fig. 6, lane 4). Taken
together, these results provide evidence that PI39-kinase/
pp70S6K pathways are involved in the antiapoptotic effect of
ET-1 in cultured cardiac myocytes.
DISCUSSION
Adult cardiac muscle cells are terminally differentiated and
lose their proliferative capacity. As a result, the maintenance
of cardiac muscle cell survival is critical for the maintenance
of normal cardiac function. The present study demonstrated
that ET-1 antagonized beta-adrenergic agonist-induced
apoptosis in cardiac myocytes and that this inhibition was
mediated mainly through ETA-dependent pathways. The
apoptotic inhibitory effect of ET-1 was neutralized by
PD098059 (an MEK-1-specific inhibitor), wortmannin (a
PI39-kinase inhibitor), and rapamycin (a pp70 S6-kinase
[pp70S6K] inhibitor), suggesting the involvement of multi-
ple signaling pathways in this inhibition.
Endothelin-1 as a protective factor against myocardial
cell apoptosis. Accumulating evidence suggests that myo-
cyte apoptosis occurs in failing hearts (5–8), indicating that
apoptosis contributes to progressive myocardial dysfunction.
However, little is known about the factors that regulate the
program of apoptosis or the molecular and cellular events
that mediate the ensuing cell death. A number of neuro-
hormonal and autocrine substances (including ET-1 and
norepinephrine) are present at high levels in patients with
heart failure (9,10). It was recently shown that beta-
adrenergic stimulation can induce apoptosis in cultured
neonatal rat cardiac myocytes (11,12).
The present study has documented that ET-1 blocked
beta-adrenergic agonist-induced apoptosis. A marked inhi-
Figure 6. The roles of MEK-1 and PI39-kinase in the ET-1-mediated inhibition of apoptosis. Cardiac myocytes were cultured in serum-free media in the
presence or absence of Iso (1025 mol/liter), ET-1 (1027 mol/liter), PD098059 (an MEK-1-specific inhibitor), wortmannin (PI39-kinase inhibitor), or
rapamycin (pp70 S6-kinase inhibitor) as indicated for 48 h. The % TUNEL-positive nuclei values were calculated by counting an average of 400 to
500 nuclei in each slide. Values are mean 6 SE of four independent experiments.
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bition by ET-1 of apoptosis in rat cardiac myocytes was
demonstrated by three lines of evidence: 1) the inhibition of
nucleosomal ladder formation of agarose gel electrophoresis;
2) the decrease in the number of TUNEL-positive cells; and
3) the decrease in the number of cells showing nuclear
condensation, a morphological feature of apoptosis. We
cannot rule out the possibility that TUNEL-positive cells
contain a subset of false-positive cells. However, stimulation
with Iso markedly increased the number of myocytes show-
ing the typical morphological features of apoptosis, whereas
ET-1 decreased the number of such myocytes. Therefore,
the number of TUNEL-positive cells correlated well with
that of morphologically evidenced apoptotic cells. Although
the levels of ET-1 required for the inhibition of apoptosis
(1028 ; 1027 mol/liter) are higher than those normally
detected in plasma, local ET-1 levels in the heart markedly
increase in the development of heart failure (15,16). Because
ET-1 accumulates within cardiac myocytes in failing hearts
as shown by immunohistochemistry (15,16), endogenous
ET-1 may function as “self-protection” by an autocrine
mechanism. Thus, it would be interesting to examine the
pathophysiological role of ET-1 as a protective factor
against apoptosis of cardiac myocytes in animal models of
heart failure.
Apoptotic inhibitory effect of ET-1 is mediated by the
ETA receptor. The members of the ET peptide family
(ET-1, ET-2 and ET-3) mediate their diverse effects
through two distinct subtypes of G protein-coupled hepta-
helical receptors, termed ETA and ETB (19,20). The ETA
receptor is selective for ET-1, and the ETB receptor does
not distinguish among these isopeptides. Vascular smooth
muscles express mainly ETA receptors mediating contrac-
tion, whereas vascular endothelium has ETB receptors that
are involved in vasodilation. Cardiac myocytes mainly ex-
press ETA receptors and a small amount of ETB receptors.
Compatible with the expression pattern in cardiac myocytes,
the present study showed that an ETA receptor antagonist
(FR139317) but not an ETB receptor antagonist (BQ788)
blocked the apoptotic inhibition by ET-1. In addition, an
ETB receptor agonist (IRL1620) did not mimic the inhib-
itory effect of ET-1. These findings are in agreement with
the idea that the apoptotic inhibitory effect of ET-1 in
cardiac myocytes is mediated mainly by the ETA receptor.
The MAP kinase-dependent pathways are required for
the protective effect of ET-1. The ETA receptor is cou-
pled to Gi as well as Gq. Signaling through Gi inhibits
adenylate cyclase, and thereby decreases the intracellular
cAMP contents (29). The present results demonstrated that
Gi pathways are not indispensable for the protective effect of
ET-1 as ET-1 also inhibited apoptosis induced by the
cell-permeable cAMP analogue 8-Br-cAMP, which in-
creases intracellular cAMP levels independent of adenylate
cyclase. Although our data do not rule out a possible role of
Gi-dependent pathways in the inhibition of apoptosis, the
nearly complete blockade of 8-Br-cAMP-mediated apopto-
sis by ET-1 suggests the important role for more down-
stream pathways in the cell survival function. The ETA
receptor-mediated signaling is functionally linked to pho-
pholipase C to induce phosphoinositide breakdown (47). It
is also becoming clear that an ETA receptor pathway
crosstalks with Ras and MAP kinase cascades (48–50).
The present findings demonstrated that the treatment of
cultured neonatal cardiac myocytes with a MEK-1-specific
inhibitor, PD098059, which has been shown specifically to
inhibit ERK1 and ERK2 activity in cardiac myocytes (32),
negated the apoptotic inhibitory effect of ET-1. These
findings demonstrate that MAP kinase-dependent path-
ways are required for the inhibition of cardiac myocyte
apoptosis. Also, MAP kinase pathways have been found to
be necessary for the effects of nerve growth factor and
insulin growth factor-1 on the promotion of the survival of
neuronal cell types (PC12), whereas inhibition of these
kinases has been shown to be critical for the induction of
apoptosis in these cells (31,33,51). The above studies
provide further evidence that MAP kinase-dependent path-
ways play an important role in promoting the survival of
terminally differentiated cell types as well.
Roles of PI3*-kinase/pp70S6K in apoptotic inhibition by
ET-1. Wortmannin, a fungal metabolite, demonstrates a
substantial degree of specificity for PI39-kinase compared
with a number of other lipid kinases. Experiments with both
PI39-kinase inhibitors and mutant growth factor receptors
have suggested that pp70S6K is one of the downstream
elements of the PI39-kinase signaling pathway (35–37).
Rapamycin inhibits the activation of pp70S6K without af-
fecting the activity of tyrosine kinase, MAP kinase, rsk-
encoded S6 kinase, or PKC in cardiac myocytes (46). The
specific inhibition of the pp70S6K activity by rapamycin is
mediated by a high-affinity binding of rapamycin to the
cellular receptor protein FRAP, a mammalian homologue of
TOR (38–45). Wortmannin and rapamycin exert distinct
effects on cell survival among different cell types. Neither
wortmannin nor rapamycin had any effect on ET-1-
mediated cell survival in fibroblasts (22).
Conversely, in PC12 cells, while wortmannin negated the
apoptotic inhibitory effect of growth factors, rapamycin
failed to induce apoptosis (33,51), suggesting that PC12 cell
survival requires a PI39-kinase signaling pathway that is
independent of pp70S6K activation. In contrast to these
results in other cells, in cardiac myocytes both rapamycin
and wortmannin almost completely inhibited the ET-1
effect of protecting the cells from apoptosis. These findings
demonstrate that PI39-kinase/pp70S6K is involved in the
protective effect of ET-1 in cardiac myocytes and that the
signaling pathways of myocardial cell survival are distinct, in
part, from those in other cell types.
Study limitations. We utilized pharmacological agents to
investigate downstream pathways that mediate apoptotic
inhibitory effects of ET-1. Although these agents have been
shown to be specific in the concentrations used in this study,
we cannot totally rule out the possibility that these agents
affected other kinase activities. This is a limitation of
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pharmacological studies. Other methodologies, such as the
use of dominant negative mutants, are needed to identify
signaling pathways that mediate protective effects by ET-1.
In addition, several possibilities should be taken into ac-
count when the data of this study are applied to human
disease.
First, a myocardial development is not complete at birth;
differences may exist between neonatal and adult cardiac
myocytes. Second, biological properties of the heart may
differ between rats and humans. Third, dissociated myocytes
in the culture may behave in a different manner with
myocytes in the organized heart in vivo. Fourth, stimulation
of normal myocytes with Iso or ET-1 may not mimic
chronic elevation of these levels in the diseased state.
However, a recent study clearly showed that myocardial cell
apoptosis results in dilation of the heart and heart failure
(52). Thus, further elucidation of the pathways for apoptosis
in cardiac myocytes will enable investigators to design new
and effective therapeutic agents for heart failure in humans.
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